Microfluidics Technology for the Design and Formulation of Nanomedicines
In conventional drug administration, drug molecules cross multiple biological barriers, distribute randomly in the tissues, and can release insufficient concentrations at the desired pathological site. Controlling the delivery of the molecules can increase the concentration of the drug in the desire...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Nanomaterials |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-4991/11/12/3440 |
| _version_ | 1797501923374399488 |
|---|---|
| author | Eman Jaradat Edward Weaver Adam Meziane Dimitrios A. Lamprou |
| author_facet | Eman Jaradat Edward Weaver Adam Meziane Dimitrios A. Lamprou |
| author_sort | Eman Jaradat |
| collection | DOAJ |
| description | In conventional drug administration, drug molecules cross multiple biological barriers, distribute randomly in the tissues, and can release insufficient concentrations at the desired pathological site. Controlling the delivery of the molecules can increase the concentration of the drug in the desired location, leading to improved efficacy, and reducing the unwanted effects of the molecules under investigation. Nanoparticles (NPs), have shown a distinctive potential in targeting drugs due to their unique properties, such as large surface area and quantum properties. A variety of NPs have been used over the years for the encapsulation of different drugs and biologics, acting as drug carriers, including lipid-based and polymeric NPs. Applying NP platforms in medicines significantly improves the disease diagnosis and therapy. Several conventional methods have been used for the manufacturing of drug loaded NPs, with conventional manufacturing methods having several limitations, leading to multiple drawbacks, including NPs with large particle size and broad size distribution (high polydispersity index), besides the unreproducible formulation and high batch-to-batch variability. Therefore, new methods such as microfluidics (MFs) need to be investigated more thoroughly. MFs, is a novel manufacturing method that uses microchannels to produce a size-controlled and monodispersed NP formulation. In this review, different formulation methods of polymeric and lipid-based NPs will be discussed, emphasizing the different manufacturing methods and their advantages and limitations and how microfluidics has the capacity to overcome these limitations and improve the role of NPs as an effective drug delivery system. |
| first_indexed | 2024-03-10T03:25:32Z |
| format | Article |
| id | doaj.art-96008111848a428fbe6bb7e1ba6becde |
| institution | Directory Open Access Journal |
| issn | 2079-4991 |
| language | English |
| last_indexed | 2024-03-10T03:25:32Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nanomaterials |
| spelling | doaj.art-96008111848a428fbe6bb7e1ba6becde2023-11-23T09:52:38ZengMDPI AGNanomaterials2079-49912021-12-011112344010.3390/nano11123440Microfluidics Technology for the Design and Formulation of NanomedicinesEman Jaradat0Edward Weaver1Adam Meziane2Dimitrios A. Lamprou3School of Pharmacy, Queen’s University Belfast, Belfast BT9 7BL, UKSchool of Pharmacy, Queen’s University Belfast, Belfast BT9 7BL, UKFluigent, 94270 Le Kremlin-Bicêtre, FranceSchool of Pharmacy, Queen’s University Belfast, Belfast BT9 7BL, UKIn conventional drug administration, drug molecules cross multiple biological barriers, distribute randomly in the tissues, and can release insufficient concentrations at the desired pathological site. Controlling the delivery of the molecules can increase the concentration of the drug in the desired location, leading to improved efficacy, and reducing the unwanted effects of the molecules under investigation. Nanoparticles (NPs), have shown a distinctive potential in targeting drugs due to their unique properties, such as large surface area and quantum properties. A variety of NPs have been used over the years for the encapsulation of different drugs and biologics, acting as drug carriers, including lipid-based and polymeric NPs. Applying NP platforms in medicines significantly improves the disease diagnosis and therapy. Several conventional methods have been used for the manufacturing of drug loaded NPs, with conventional manufacturing methods having several limitations, leading to multiple drawbacks, including NPs with large particle size and broad size distribution (high polydispersity index), besides the unreproducible formulation and high batch-to-batch variability. Therefore, new methods such as microfluidics (MFs) need to be investigated more thoroughly. MFs, is a novel manufacturing method that uses microchannels to produce a size-controlled and monodispersed NP formulation. In this review, different formulation methods of polymeric and lipid-based NPs will be discussed, emphasizing the different manufacturing methods and their advantages and limitations and how microfluidics has the capacity to overcome these limitations and improve the role of NPs as an effective drug delivery system.https://www.mdpi.com/2079-4991/11/12/3440drug deliveryliposomesmicrofluidicsnanoparticlesnanomedicinePLGA |
| spellingShingle | Eman Jaradat Edward Weaver Adam Meziane Dimitrios A. Lamprou Microfluidics Technology for the Design and Formulation of Nanomedicines Nanomaterials drug delivery liposomes microfluidics nanoparticles nanomedicine PLGA |
| title | Microfluidics Technology for the Design and Formulation of Nanomedicines |
| title_full | Microfluidics Technology for the Design and Formulation of Nanomedicines |
| title_fullStr | Microfluidics Technology for the Design and Formulation of Nanomedicines |
| title_full_unstemmed | Microfluidics Technology for the Design and Formulation of Nanomedicines |
| title_short | Microfluidics Technology for the Design and Formulation of Nanomedicines |
| title_sort | microfluidics technology for the design and formulation of nanomedicines |
| topic | drug delivery liposomes microfluidics nanoparticles nanomedicine PLGA |
| url | https://www.mdpi.com/2079-4991/11/12/3440 |
| work_keys_str_mv | AT emanjaradat microfluidicstechnologyforthedesignandformulationofnanomedicines AT edwardweaver microfluidicstechnologyforthedesignandformulationofnanomedicines AT adammeziane microfluidicstechnologyforthedesignandformulationofnanomedicines AT dimitriosalamprou microfluidicstechnologyforthedesignandformulationofnanomedicines |